Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.24

+5.1%

12:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (7252)	10/28/2002 2:40:19 PM
From: Biomaven	Read Replies (1) of 52153

there is apparently a significant difference in the patient populations that you now see for RA trials Perhaps making me eat my words, the Rituxan Phase II results (24 weeks) look every bit as good as Enbrel/Remicade, maybe better. Certainly a lot more convenient for the patient, not to mention a lot cheaper - I guess safety issues will be the key factor going forward, although of course the TNF-inhibitors have their own concerns as well. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next